Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Advanced Financial Summary 
jyotsna singhal
Nov 28, 2022 3:57PM ET
What’s going on really 🥹🥹🥹
0
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
2.2200
-0.0300
-1.33%
Type:
Equity
Market:
United States
- Volume: 25,020
- Bid/Ask: 0.0000 / 0.0000
- Day's Range: 2.2100 - 2.2700
Check Cap Ltd
2.2200
-0.0300
-1.33%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Financial Summary
- Income Statement
- Balance Sheet
- Cash Flow
- Ratios
- Dividends
- Earnings
NASDAQ:CHEK Financials
A brief overview of the NASDAQ:CHEK financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Check Cap Ltd over time.
Check-Cap Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 2.59 million compared to USD 4.75 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.81 a year ago. Diluted loss per share from continuing operations was USD 0.44 compared to USD 0.81 a year ago.For the nine months, net loss was USD 13.91 million compared to USD 15.4 million a year ago. Basic loss per share from continuing operations was USD 2.38 compared to USD 2.74 a year ago. Diluted loss per share from continuing operations was USD 2.38 compared to USD 2.74 a year ago.
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter
CHEK Income Statement
Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM -42.65%
Total Revenue Net Income
| Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Total Revenue | ||||
| Gross Profit | ||||
| Operating Income | -2.86 | -6.06 | -4.85 | -4.22 |
| Net Income | -2.59 | -6.88 | -4.44 | -3.71 |
CHEK Balance Sheet
Quick Ratio MRQ 17.17
Current Ratio MRQ 17.6
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.11%
Total Assets Total Liabilities
| Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Total Assets | 29.03 | 33.72 | 41.31 | 45.44 |
| Total Liabilities | 1.64 | 3.54 | 4.29 | 4.13 |
| Total Equity | 27.4 | 30.19 | 37.02 | 41.31 |
CHEK Cash Flow Statement
Cash Flow/Share TTM -3
Revenue/Share TTM -
Operating Cash Flow -218.90%
Cash Net Change in Cash
| Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
| Cash From Operating Activities | -3.59 | -5.2 | -4.63 | -4.15 |
| Cash From Investing Activities | 4.5 | -9.02 | 17 | -1.11 |
| Cash From Financing Activities | 0 | |||
| Net Change in Cash | 0.909 | -14.21 | 12.38 | -5.26 |
* In Millions of USD (except for per share items)
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Write your thoughts about Check Cap Ltd
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Vladimir Ivanov
Aug 29, 2022 3:10PM ET
$10 in few weeks! (after r/s)
0
0
Vladimir Ivanov
Jun 21, 2022 8:27AM ET
today is the day!
1
0
Sandeep Karwa
Jun 21, 2022 8:27AM ET
What is the good news ?
0
0
yesyes yes yes yes
Apr 21, 2022 7:40AM ET
This is an easy $2.50 stock on trials ending
1
0
Vincent Ornells
Apr 01, 2022 1:46PM ET
Clinical trials begin April 15th 2022
3
0
Sandeep Karwa
Apr 01, 2022 1:46PM ET
How is the outlook short and long term ?
0
0
DEMOLITION MIND
Feb 07, 2022 10:24PM ET
Fda approval of pivotal study!!!
1
0
DEMOLITION MIND
Feb 01, 2022 8:50PM ET
We may see the moon soon
0
0
DEMOLITION MIND
Dec 09, 2021 3:30AM ET
Countdown..
0
0
DEMOLITION MIND
Dec 03, 2021 4:35PM ET
Com’oooon maaan!!!!
1
1
DEMOLITION MIND
Nov 25, 2021 2:32AM ET
For those new to Check Cap Here are some key pointsCheck Cap's C-Scan pill for colonoscopy has been approved for use in Isreal since 2018. https://www.prnewswire.com/news-releases/check-cap-receives-approval-from-the-israeli-ministry-of-health-to-initiate-commercial-sales-in-israel-of-its-c-scan-system-300706973.htmlCheck Cap's Scan tech requires no preparatory procedure which makes follow through with the procedure much easier and less impactful to individual's lives. Patients do not have to experience pain and discomfort from procedure like they do colonoscopies. They also do not need the same facility use as a colonoscopy allowing people to save time.The FDA is particularly interested in Chek because roughly 40% of Americans who should get a colonoscopies don't. Existing non-invasive colon screening is less acurate than C-scan Tech used by Check Cap.Recent study https://www.businesswire.com/news/home/20150428006203/en/New-Study-Reveals-People-Avoid-Colonoscopy
1
0
DEMOLITION MIND
Nov 25, 2021 2:32AM ET
28 percent do not feel it is necessary20.1 percent say it’s too expensive20.1 percent dislike the procedure itself (addressed by Check Cap)15.8 percent rely on other methods to avoid colon cancer (addressed by Check Cap)6.5 percent do not know they are supposed to get one6.5 percent are too busy with other priorities (addressed by Check Cap)Additionally Chek has already raised a large amount of capitolthis year that it expects will carry it through a stage 3 study for the US. Simplywall.st reports they should have enough capitol for 3 years of funding, but this does not account for large scale studies like a phase II and III trial. Covid delayed C-Scan US clinical testing as the FDA was unable to get to Israel in order to inspect the facility.Covid also highlighted challenges to Check Cap's supply chain as they previously used a single supplier, this is something management has been addressing and they have expressed confidence that their expansion and supply chain changes wi
0
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review